adenocarcinoma – Newsemia

Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin

NewsemiaJuly 3, 2020

by NewsemiaJuly 3, 202000

Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin Source link...

Gastroenterology

Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study

NewsemiaJuly 1, 2020

by NewsemiaJuly 1, 202000

Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study Source link...

Gastroenterology

A microRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases

NewsemiaJune 27, 2020

by NewsemiaJune 27, 202000

Pancreatic ductal adenocarcinomas (PDACs) frequently metastasize to the lymph nodes; strategies are needed to identify patients at highest risk for lymph node metastases. We performed...

Gastroenterology

Use of Immunostaining for the diagnosis of Lymphovascular invasion in superficial Barrett’s esophageal adenocarcinoma

NewsemiaJune 6, 2020

by NewsemiaJune 6, 2020022

The prevalence of Barrett’s esophageal adenocarcinoma (BEA) is increasing in Japan. Accurate assessment of lymphovascular invasion (LVI) after endoscopic resection or surgery is essential in...

Gastroenterology

Chromosomal and molecular pathway alterations in the neuroendocrine carcinoma and adenocarcinoma components of gastric mixed neuroendocrine–nonneuroendocrine neoplasm

NewsemiaMay 27, 2020

by NewsemiaMay 27, 2020028

Chromosomal and molecular pathway alterations in the neuroendocrine carcinoma and adenocarcinoma components of gastric mixed neuroendocrine–nonneuroendocrine neoplasm Source link...

Gastroenterology

Neoadjuvant therapy-induced sarcopenia, reduced OS linked in pancreatic ductal adenocarcinoma

NewsemiaMay 23, 2020

by NewsemiaMay 23, 202002

Neoadjuvant therapy-induced sarcopenia in patients who underwent neoadjuvant therapy for pancreatic ductal adenocarcinoma correlated with increased disease recurrence and overall mortality, and reduced overall survival,...

Gastroenterology

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

NewsemiaMay 19, 2020

by NewsemiaMay 19, 202005

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis Source link...

Gastroenterology

Novel microRNA biomarker could help detect lymph node metastases in pancreatic cancer patients

NewsemiaMay 19, 2020

by NewsemiaMay 19, 202002

For years, surgeons have operated on pancreatic cancer patients to remove what they thought was a localized tumor only to discover that the disease had...

Gastroenterology

Exosomal miR-21 promotes proliferation, invasion and therapy resistance of colon adenocarcinoma cells through its target PDCD4

NewsemiaMay 19, 2020

by NewsemiaMay 19, 202004

Exosomal miR-21 promotes proliferation, invasion and therapy resistance of colon adenocarcinoma cells through its target PDCD4 Source link...

Gastroenterology

Notch Signaling Mediates Differentiation in Barrett’s Esophagus and Promotes Progression to Adenocarcinoma

NewsemiaApril 21, 2020

by NewsemiaApril 21, 2020027

Studies are needed to determine the mechanism by which Barrett´s esophagus (BE) progresses to esophageal adenocarcinoma (EAC). Notch signaling maintains stem cells in the gastrointestinal...

Gastroenterology

PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC

NewsemiaApril 17, 2020

by NewsemiaApril 17, 2020012

PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the...

Gastroenterology

Diagnosis of vascular invasion in pancreatic ductal adenocarcinoma using endoscopic ultrasound elastography

NewsemiaMarch 31, 2020

by NewsemiaMarch 31, 2020023

Vascular invasion is an important criterion for resectability and deciding the therapeutic strategy for pancreatic ductal adenocarcinoma (PDAC), but imaging diagnosis is currently difficult. Endoscopic...

Gastroenterology

Carcinogenesis of Pancreatic Ductal Adenocarcinoma

NewsemiaMarch 19, 2020

by NewsemiaMarch 19, 202004

Although the estimated time for development of pancreatic ductal adenocarcinoma (PDA) is more than 20 years, PDAs are usually detected at late, metastatic stages. PDAs...

Gastroenterology

Correction: PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability

NewsemiaMarch 4, 2020

by NewsemiaMarch 4, 2020040

Correction: PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability Source link...

Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma

NewsemiaFebruary 17, 2020

by NewsemiaFebruary 17, 2020032

Noorani, A; Li, X; Goddard, M; Crawte, J; Alexandrov, LB; Secrier, M; Eldridge, MD; … Fitzgerald, RC; + view all Noorani, A; Li, X; Goddard,...

Gastroenterology

TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

NewsemiaFebruary 17, 2020

by NewsemiaFebruary 17, 2020043

TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial Source link...

Gastroenterology

Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels

NewsemiaFebruary 15, 2020

by NewsemiaFebruary 15, 2020043

Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels Source link...

Gastroenterology

BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma

NewsemiaFebruary 10, 2020

by NewsemiaFebruary 10, 2020034

BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma Source link...

Gastroenterology

Identification of Subtypes of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data

NewsemiaFebruary 5, 2020

by NewsemiaFebruary 5, 2020050

Esophageal adenocarcinomas (EAC) are heterogeneous and often preceded by Barrett’s esophagus (BE). Many genomic changes have been associated with development of BE and EAC, but...

Gastroenterology

VGLL3 is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in stomach adenocarcinoma

NewsemiaFebruary 4, 2020

by NewsemiaFebruary 4, 2020032

VGLL3 is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in stomach adenocarcinoma Source link...

Newsemia

Tag: adenocarcinoma

Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin

Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study

A microRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases

Use of Immunostaining for the diagnosis of Lymphovascular invasion in superficial Barrett’s esophageal adenocarcinoma

Chromosomal and molecular pathway alterations in the neuroendocrine carcinoma and adenocarcinoma components of gastric mixed neuroendocrine–nonneuroendocrine neoplasm

Neoadjuvant therapy-induced sarcopenia, reduced OS linked in pancreatic ductal adenocarcinoma

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

Novel microRNA biomarker could help detect lymph node metastases in pancreatic cancer patients

Exosomal miR-21 promotes proliferation, invasion and therapy resistance of colon adenocarcinoma cells through its target PDCD4

Notch Signaling Mediates Differentiation in Barrett’s Esophagus and Promotes Progression to Adenocarcinoma

PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC

Diagnosis of vascular invasion in pancreatic ductal adenocarcinoma using endoscopic ultrasound elastography

Carcinogenesis of Pancreatic Ductal Adenocarcinoma

Correction: PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability

Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma

TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels

BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma

Identification of Subtypes of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data

VGLL3 is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in stomach adenocarcinoma

COVID-19